Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of EgyVax for COVID-19
NCT05218070Phase 1Unknown
- Sponsor
- EVA Pharma
- Start
- Feb 2022
- Primary completion
- Oct 2022
- Modality
- Whole Inactivated Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of EgyVax in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by EVA Pharma. Primary endpoints: Safety of EgyVax Vaccine after 1 month from the first vaccination dose and Safety of EgyVax Vaccine up to 6 months of the first vaccination dose. Status: unknown.
02
Drugs
EgyVax
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05218070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05218070.